The serum soluble HLA-DR antigens as a predictive marker of the response to interferon-alpha treatment in patients with chronic hepatitis C
- PMID: 11368209
The serum soluble HLA-DR antigens as a predictive marker of the response to interferon-alpha treatment in patients with chronic hepatitis C
Abstract
The serum concentrations of soluble HLA-DR antigens (sDR) were monitored in 40 patients with chronic hepatitis C (CHC) who received interferon treatment. The expression of HLA-class II antigens in liver tissues was also studied by immunohistochemistry. The sDR levels in patients with chronic hepatitis C were significantly higher than those in healthy subjects (416+/-236 [mean +/- S.D.] ng/ml vs. 286+/-163 ng/ml) (P<0.05). There was no correlation between the sDR levels and serum alanine aminotransferase levels, suggesting that sDR do not reflect the extent of liver necrosis. Although there was no difference in pretreatment sDR levels between interferon complete responders and non-responders, sDR significantly declined in complete responders, while they did not in non-responders. The hepatic expression of HLA-DR antigens was observed in dendritic cells, lymphocytes and Kupffer cells in portal area, while in Kupffer cells and endothelial cells in central acinus. These expression significantly decreased in complete responders. From these results, sDR, reflecting the hepatic expression of HLA-DR antigens, could be a predictive marker of response to inteferon treatment.
Similar articles
-
Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.Rev Invest Clin. 2002 Jan-Feb;54(1):41-50. Rev Invest Clin. 2002. PMID: 11995406
-
Chronic hepatitis C in the advanced adult and elderly subjects.Minerva Gastroenterol Dietol. 2009 Jun;55(2):145-57. Minerva Gastroenterol Dietol. 2009. PMID: 19305374 Review.
-
Changes of hepatic vitronectin levels in patients with chronic hepatitis C treated with interferon alpha.Res Commun Mol Pathol Pharmacol. 1999;104(3):253-63. Res Commun Mol Pathol Pharmacol. 1999. PMID: 10741376 Clinical Trial.
-
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.Hepatology. 2005 Mar;41(3):643-51. doi: 10.1002/hep.20592. Hepatology. 2005. PMID: 15726647
-
Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.Hepatogastroenterology. 2007 Mar;54(74):493-8. Hepatogastroenterology. 2007. PMID: 17523306
Cited by
-
Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy.Immunology. 2002 Nov;107(3):281-7. doi: 10.1046/j.1365-2567.2002.01518.x. Immunology. 2002. PMID: 12423303 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous